1	Critical Role for 24-Hydroxylation in Homeostatic Regulation of Vitamin D Metabolism
2	
3	Zhinous Shahidzadeh Yazdi, Elizabeth A. Streeten, Hilary B. Whitlatch,
4	May E. Montasser, Amber L. Beitelshees, and Simeon I. Taylor
5	
6	Department of Medicine
7	Division of Endocrinology, Diabetes, and Nutrition
8	University of Maryland School of Medicine
9	Baltimore, MD, USA
10	
11	Corresponding author: Simeon I. Taylor, MD, PhD, Department of Medicine, University of
12	Maryland School of Medicine, Baltimore, MD 21201, USA
13	Telephone number: +1 301 980 5272
14	Email: staylor2@som.umaryland.edu
15 16 17 18 19 20	<u>Conflict-of-interest statement:</u> SIT serves as a consultant for Ionis Pharmaceuticals and receives an inventor's share of royalties from NIDDK for metreleptin as a treatment for generalized lipodystrophy. EAS, MEM, and HBW receive research support (unrelated to this project) from the Regeneron Genetics Center. ZSY and ALB have no conflicts to disclose.
21	Trial registration: NCT02891954 (clinicaltrials.gov)
22 23	<u>Funding</u> : National Institute of Diabetes, Digestive, and Kidney Diseases: R01DK118942, R01DK118924-02S1, and T32DK098107
24 25	<u>Key words</u> : vitamin D deficiency, 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, 25- hydroxyvitamin D, parathyroid hormone, homeostatic regulation
26	ORCID ID# (Simeon I. Taylor): 0000-0001-7500-7854

27 ABSTRACT

28

29	Context. The body	y has evolved	homeostatic	mechanisms to	o maintain	free 1	evels of	Ca^{+2}	2 and
----	-------------------	---------------	-------------	---------------	------------	--------	----------	-----------	----------

- 30 1,25-dihydroxyvitamin D [1,25(OH)₂D] within narrow physiological ranges. Clinical guidelines
- emphasize important contributions of PTH in maintaining this homeostasis.
- 32 *Objective*. To investigate mechanisms of homeostatic regulation of vitamin D (VitD) metabolism
- and to apply mechanistic insights to improve clinical assessment of VitD status.
- 34 *Design*. Crossover clinical trial studying participants before and after VitD3-supplementation.
- 35 *<u>Setting</u>*. Community.
- 36 *Participants*. 11 otherwise healthy individuals with VitD-deficiency (25-hydroxyvitamin D

37 $[25(OH)D] \leq 20 \text{ ng/mL}).$

Interventions. VitD3-supplements (50,000 IU once or twice a week depending on BMI, for 4-6
 weeks) were administered to achieve 25(OH)D>30 ng/mL.

- 40 <u>Results.</u> VitD3-supplementation significantly increased mean 25(OH)D by 2.7-fold and 24,25-
- 41 dihydroxyvitamin D [24,25(OH)₂D] by 4.3-fold. In contrast, mean levels of PTH, FGF23, and
- 42 1,25(OH)₂D did not change. Mathematical modeling suggested that 24-hydroxylase activity was
- 43 maximal for $25(OH)D \ge 50$ ng/mL and achieved a minimum (~90% suppression) with
- 44 25(OH)D<10-20 ng/mL. The 1,25(OH)₂D/24,25(OH)₂D ratio better predicted modeled 24-
- 45 hydroxylase activity (h) (ρ =-0.85; p=0.001) compared to total plasma 25(OH)D (ρ =0.51; p=0.01)
- 46 and the $24,25(OH)_2D/25(OH)D$ ratio ($\rho=0.37$; p=0.3).
- 47 *Conclusions*. Suppression of 24-hydroxylase provides a first line of defense against symptomatic
- 48 VitD-deficiency by decreasing metabolic clearance of $1,25(OH)_2D$. The

- 49 1,25(OH)₂D/24,25(OH)₂D ratio provides a useful index of VitD status since it incorporates
- 50 24,25(OH)₂D levels and therefore, provides insight into 24-hydroxylase activity. When VitD
- 51 availability is limited, this suppresses 24-hydroxylase activity thereby decreasing the level of
- 52 $24,25(OH)_2D$ and increasing the $1,25(OH)_2D/24,25(OH)_2D$ ratio. Thus, an increased
- $1,25(OH)_2D/24,25(OH)_2D$ ratio signifies triggering of homeostatic regulation, which occurs at
- 54 early stages of VitD-deficiency.

55 INTRODUCTION:

Vitamin D (VitD) plays an essential role in mediating absorption of dietary calcium in the 56 57 intestine (1-4). Furthermore, as evidenced by diseases such as nutritional rickets, VitD is critical to maintaining bone health (5, 6). The body obtains VitD from two sources. Endogenous 58 production of VitD requires exposure to ultraviolet light, which is variable depending on 59 60 geographic location and the season of the year among other factors. Dietary intake of VitD is also variable and depends on the VitD content of the diet (including intake of fortified dairy products 61 62 and dietary supplements) (7, 8). To maintain a consistent milieu intérieure (9, 10), each individual must maintain levels of free 1,25-dihydroxyvitamin D [1,25(OH)₂D] - the 63 biologically active metabolite of VitD – within a narrow physiological range notwithstanding 64 considerable variation in availability of the biosynthetic precursor (i.e., VitD) (11-13). 65 We developed a mathematical model to investigate physiological mechanisms mediating 66 homeostatic regulation of VitD metabolism. 24-hydroxylation provides the major mechanism 67 whereby $1,25(OH)_2D$ is cleared (12, 14, 15). According to our mathematical model, *in vivo* 68 activity of 24-hydroxylase varies over an approximately tenfold range. 24-Hydroxylase activity 69 achieves a maximum when 25(OH)D levels exceed 50 ng/mL. By inducing 24-hydroxylase 70 activity when VitD is abundant, the body increases clearance of $1,25(OH)_2D$ – thereby protecting 71 against VitD toxicity. Furthermore, the model suggests that 24-hydroxylase activity achieves a 72 73 minimum when 25(OH)D is less than 10-20 ng/mL. The resultant decrease in $1,25(OH)_2D$ clearance tends to sustain 1,25(OH)₂D levels, thereby compensating for limited availability of 74 VitD and protecting against symptomatic VitD deficiency. 75 76 Several feedback loops contribute to homeostatic regulation of VitD – including feedback loops

between VitD status and the rates of both production and clearance of $1,25(OH)_2D$ (12, 16-19).

4

Cannon proposed the concept of the "wisdom of the body" (9), which includes homeostatic 78 mechanisms that are responsible for maintaining a constant *milieu intérieure*. Endocrinologists 79 often leverage the "wisdom of the body" to diagnose states of hormonal excess or hormonal 80 insufficiency based on the level of activation or suppression of homeostatic mechanisms. This is 81 exemplified by the approach to diagnosing patients' hormonal status with respect to hormones 82 83 that act upon other nuclear hormone receptors (e.g., thyroid hormones or glucocorticoids) by measuring the levels of trophic hormones (e.g., TSH or ACTH) (20, 21). By analogy, we discuss 84 our data in the context of the published literature advocating for a similar approach to assessing 85 86 VitD status – i.e., by assessing the level of suppression/induction of 24-hydroxylase activity (22-24). By leveraging the wisdom of the body in this assessment, physicians can advance the state-87 of-the-art of assessment of VitD status. 88

The present work is a supplemental analysis of data obtained in a clinical trial investigating the nutrient-drug interaction between VitD and canagliflozin (13). That clinical trial provided data on the responses of PTH and VitD metabolites to VitD3 supplementation in participants whose baseline 25(OH)D was in the range of 10-20 ng/mL. We developed a mathematical model to investigate regulatory mechanism mediating these responses and also considered the clinical implications of the predictions by this model.

95 METHODS

This study ("VitD Sub-study") was part of our ongoing "Genetics of Response to Canagliflozin 96 97 (GRC)" clinical trial (Clinicaltrials.gov Identifier: NCT02891954) in healthy volunteers recruited from the Old Order Amish population in Lancaster PA, who are non-Hispanic white people. 98 Although participants were excluded from the parent study if their 25(OH)D level ≤ 20 ng/mL, 99 100 these VitD deficient individuals were eligible to participate in the VitD Sub-study, which investigated the effects of VitD3 supplements on canagliflozin-triggered changes in the serum 101 102 phosphorus/FGF23/1,25(OH)₂D/PTH axis (13). Participants were required to meet all other 103 inclusion/exclusion criteria for the parent study. The effect of VitD3 supplementation on canagliflozin-induced changes in mineral metabolism biomarkers was reported elsewhere (13). 104 105 The current paper reports results of a secondary data analysis focusing primarily on the effect 106 VitD3 supplementation on VitD metabolites in participants with mild-moderate VitD deficiency. Screening and recruitment: 107 As reported previously, we screened 24 healthy volunteers from September 2019 to July 2021 108 and enrolled 19 individuals with 25(OH)D levels ≤ 20 ng/mL who were otherwise eligible to 109 participate in the parent GRC study (13). The Endocrine Society's clinical practice guidelines 110 proposed thresholds of 25(OH)D \leq 20 ng/mL (\leq 50 nmol/L) for VitD deficiency, 21-29 ng/mL 111 (51-74 nmol/L) for VitD insufficiency, and \geq 30 ng/mL (\geq 75 nmol/L) for VitD sufficiency (17). 112 113 We applied The Endocrine Society's definition of VitD deficiency (≤20 ng/mL) as a key inclusion criterion for this sub-study and applied the definition of VitD sufficiency (\geq 30 ng/mL) 114 as the criterion for adequacy of VitD3 supplementation. Details of demographics, baseline 115 116 characteristics, recruitment, and disposition are reported elsewhere (13). Because of interruptions and delays associated with the COVID-19 pandemic, we did not complete our plan to study 25 117

research participants. We analyzed data after eleven participants (four females and seven males)completed the entire study protocol.

120 *Endpoints and biomarkers:*

- 121 We measured levels of the following biomarkers both at baseline and after VitD3
- supplementation: plasma PTH, plasma FGF23, serum phosphorus, serum calcium, and three
- 123 VitD metabolites -25(OH)D, $1,25(OH)_2D$, and 24,25-dihydroxyvitamin D [$24,25(OH)_2D$].

124 *VitD3 supplementation protocol*

- 125 VitD deficient participants completed canagliflozin challenge #1 and then received VitD3
- 126 capsules (Bio-Tech Pharmacal; Fayetteville, AR) in doses of either 50,000 IU per week for
- participants with BMI $<30 \text{ kg/m}^2$ or 50,000 IU twice a week for participants with BMI $\ge 30 \text{ kg/m}^2$
- 128 for four weeks, followed by a second total serum 25(OH)D measurement a week after
- 129 completion of the four-week VitD3 supplementation protocol (13). If screening serum 25(OH)D
- 130 levels (Quest Diagnostics) were <30 ng/mL, high-dose VitD3 supplementation was continued.
- 131 Once screening 25(OH)D (Quest Diagnostics) levels were confirmed to be \geq 30 ng/mL,
- 132 participants were administered the maintenance dose of VitD3 supplementation (1000 IU/d or
- 133 2000 IU/d for BMI <30 kg/m² or BMI \ge 30 kg/m², respectively) for at least six weeks to allow
- them to re-equilibrate to a lower physiologic dose and to develop a new steady state. The
- 135 maintenance dose was continued until completion of canagliflozin challenge #2.

136 <u>Clinical chemistry</u>

- 137 Blood samples obtained at home visits were collected in test tubes as appropriate for each assay
- 138 (13). Quest Diagnostics conducted an immunoassay for baseline levels of plasma PTH as well as
- 139 LC-MS/MS assays to measure baseline serum 1,25(OH)₂D, and serum 25(OH)D levels. Plasma

140	levels of 25(OH)D and 24,25(OH)2D were assessed using LC-MS/MS assays conducted by
141	Heartland Assays (Ames, IA). Quest's serum 25(OH)D levels were used to determine eligibility
142	for the VitD Sub-study. Heartland's plasma 25(OH)D levels were used to assess the response to
143	VitD3 supplements. Participants were recruited to the parent study, which used Quest's 25(OH)D
144	assay to screen for eligibility. Therefore, eligibility for the sub-study was also based on Quest's
145	assay. The VitD sub-study used Heartland's assay to obtain data on 24,25(OH)2D levels. We also
146	used Heartland's 25(OH)D assay to obtain data on 25(OH)D levels on the same day we obtained
147	all the other data in the study. In contrast, the screening data on 25(OH)D were typically obtained
148	at least one to two weeks prior to conducting the actual studies. We wanted to compare 25(OH)D
149	levels on the day of screening to the 25(OH)D level on the day of the actual study to determine
150	whether 25(OH)D levels had changed during that time interval. We have reported 25(OH)D and
151	$24,25(OH)_2D$ in ng/mL and $1,25(OH)_2D$ in pg/mL. Multiplication by a factor of 2.49 can be used
152	to convert from ng/mL to nmol/L. Mean levels for 25(OH)D before and after VitD3
153	supplementation, were identical in assays conducted by Quest Diagnostics and Heartland Assays
154	(13). LC-MS/MS assays conducted at both Quest Diagnostics and Heartland Assays
155	distinguished between derivatives of VitD2 and VitD3. Derivatives of VitD2 were not detected
156	in any of our participants' samples. For simplicity, we refer to our data on levels of 25(OH)D,
157	1,25(OH) ₂ D, or 24,25(OH) ₂ D without specifying D2 or D3. Nevertheless, since D2 derivatives
158	were not detected in any of our participants, this should be understood as referring exclusively to
159	D3 derivatives.

160 *Quality control for VitD assays of VitD metabolites*

Heartland Assays provided the following information regarding their assays of 25(OH)D and
24,25(OH)₂D: (a) accuracy >90% based on comparisons to National Institute of Standards and

Technology standards; and (b) coefficients of variation for both inter- and intra-assay
comparisons were < 5%.

165 Analysis of our data. We obtained blood samples on three separate days during canagliflozin 166 (300 mg/day) challenge tests: baseline prior to receiving canagliflozin, at 48 hours (after receiving canagliflozin for two days), and at 120 hours (after receiving canagliflozin for five 167 168 days). Because mean levels of 25(OH)D and 24,25(OH)₂D were not affected by canagliflozin, we calculated coefficients of variation based on an assumption that the three separate blood 169 samples obtained from each individual during the canagliflozin challenge test had similar 170 171 concentrations of those two VitD metabolites. Based on this assumption, we calculated coefficients of variation of 5.8% for 25(OH)D and 11.1% for 24,25(OH)₂D. Because these 172 173 calculated coefficients of variation included day-to-day variation in VitD metabolite levels as 174 well as intra-assay variation, our estimates of coefficients of variation are likely greater than the actual intra-assay variation. 175

176 Furthermore, we compared mean data for 25(OH)D levels measured in the same individuals in the two assays. Mean 25(OH)D levels before receiving VitD3 supplements were 16.4 and 16.5 177 ng/mL in the Quest and Heartland assays, respectively (13). Mean total 25(OH)D levels after 178 receiving VitD3 supplements were 45.3 and 44.3 ng/mL in the Quest and Heartland assays, 179 respectively (13). In addition, the individual data from the Quest assay (blood obtained on the 180 day of screening) was highly correlated with individual data from the Heartland assay (blood 181 obtained on Day 1 of the canagliflozin challenge test) – with variance in one assay accounting 182 for 81% of the variance in the other assay. Based on these data, we conclude that the two assays 183 184 provide comparable measurements of 25(OH)D levels. In any case, the Quest assay for 25(OH)D

was used only to determine eligibility for the study. The Heartland assay was the sole source of
data on 25(OH)D levels used for determination of goodness-of-fit for our model.

- 187 *Published analysis of Quest's assay of 1,25(OH)*₂*D*.
- 188 Biancuzzo et al. (25) reported intra- and inter-assay coefficients of variation of 9% and 12%,
- respectively, for Quest's assay of 1,25(OH)₂D. In addition, we estimated the inter-assay
- 190 coefficient of variation based on our observation that $1,25(OH)_2D$ levels were not changed by
- administration of VitD3 supplements. When we calculated a coefficient of variation for
- 192 1,25(OH)₂D levels before and after VitD3 supplementation, we estimated a coefficient of
- variation of 13% very similar to the inter-assay coefficient of variation reported by Biancuzzo

194 et al. (25). Our calculation of coefficient of variation includes at least three components: the

- 195 coefficient of variation for measurement error, day-to-day variation, and a possible small effect
- of VitD3 supplementation on 1,25(OH)₂D levels. Thus, our estimate of the coefficient of
- 197 variation represents an upper bound for the actual inter-assay coefficient of variation.

198 <u>Mathematical Modeling</u>

We developed a mathematical model to analyze relationships among 25(OH)D, 1,25(OH)₂D, and
24,25(OH)₂D. See Table 1 for definitions of model parameters. For the purpose of fitting curves
to model our clinical trial data, we estimated model parameters using an iterative trial and error
approach.

The observed sigmoid curve expressing the concentration of total 24,25(OH)₂D as a function of total 25(OH)D was fitted by an equation with the form of Equation (1):

205 (1)
$$S(24,25) = \frac{(\frac{W24}{L24})e^{aS(25)}}{1+\frac{e^{aS(25)}}{L24}}$$

- where S(25) and S(24,25) represent levels of 25(OH)D and $24,25(OH)_2D$, respectively; W_{24} and
- 207 L₂₄ represent analogs of the maximal velocity and Michaelis-Menten constant for 24-
- 208 hydroxylase enzyme, respectively, with 25(OH)D as substrate; α is a model parameter to
- 209 facilitate fitting the equation to the observed data.
- The model assumes that $24,25(OH)_2D$ is cleared by a first order process with a rate constant of
- 211 *m*(24,25) [Equation (1a)]:

212 (1a) Rate of clearance of 24,25(*OH*)₂
$$D = m(24,25) \frac{(\frac{W24}{L24})e^{aS(25)}}{1+\frac{e^{aS(25)}}{L24}}$$

We hypothesized that the 24-hydroxylase enzyme follows Michaelis-Menten kinetics asdescribed by Equation (2):

215 (2) Production of 24,25(OH)₂
$$D = \frac{V24 \times h \times S(25)}{K24 + S(25)}$$

where S(25) represents the level of 25(OH)D; V_{24} and K_{24} represent the maximal velocity and

217 Michaelis-Menten constant for 24-hydroxylase enzyme, respectively, with 25(OH)D as substrate.

218 h is a variable function of S(25) that represents 24-hydroxylase activity as a fraction of the

219 maximally induced level of the enzyme observed when 25(OH)D levels are high.

At steady state, the rate of production of 24,25(OH)₂D [Equation (2)] is equal to the rate at which

221 $24,25(OH)_2D$ is cleared [Equation (1a)]. Accordingly, the value of h can be calculated by

222 Equation (3):

223 (3)
$$h = m(24,25) \frac{\binom{W24}{L24} e^{aS(25)}}{1 + \frac{e^{aS(25)}}{L24}} \div \frac{V24 \times S(25)}{K24 + S(25)}$$

Genetic evidence demonstrates the critical role of CYP24A1-mediated 24-hydroxylation in
inactivation of 1,25(OH)₂D (26, 27). Homozygosity for loss of function mutations in *CYP24A1*

has been reported to cause hypercalcemia – presumably due to excessive levels of 1,25(OH)₂D.

227 Since CYP24A1 catalyzes 24-hydroxylation of both 25(OH)D and 1,25(OH)₂D, we modified

Equation (1a) to yield Equation (4):

229 (4) Rate of clearance of
$$1,25(OH)_2 D = m(1,25) \frac{\binom{W1,25}{L1,25}e^{aS(1,25)}}{1+\frac{e^{aS(1,25)}}{L1,25}}$$

where S(1,25) represents the level of 1,25(OH)₂D; $W_{1,25}$ and $L_{1,25}$ represent analogs of the

231 maximal velocity and Michaelis-Menten constant for 24-hydroxylase enzyme, respectively, with

 $1,25(OH)_2D$ as substrate; α is a model parameter that facilitates fitting the equation to the

observed data; and m(1,25) is a first-order rate constant analogous to m(24,25) in Equation (1a).

Further, we hypothesize that CYP27B1-mediated 1α-hydroxylation of 25(OH)D follows

235 Michaelis-Menten kinetics:

236 (5) Production of
$$1,25(OH)_2D = \frac{V1 \times S(25)}{K1+S(25)}$$

where V₁ and K₁ represent the maximal velocity and Michaelis-Menten constant for 1 α hydroxylase, respectively, with 25(OH)D as substrate. Under steady state conditions, the rates of production and metabolic clearance of 1,25(OH)₂D are equal. Thus, we can combine Equations (4) and (5) to yield Equation (6):

241 (6)
$$\frac{V1 \times S(25)}{K1 + S(25)} = m(1,25) \frac{\left(\frac{W1,25}{L1,25}\right)e^{aS(1,25)}}{1 + \frac{e^{aS(1,25)}}{L1,25}}$$

242 Solving for S(1,25), we obtain Equation (7):

243 (7)
$$S(1,25) = \{Ln[S(25)] - Ln\left[m_{1,25} + \frac{S(25)}{K_1}\left(m_{1,25} - \frac{V_1}{W_{1,25}}\right)\right] - Ln\frac{W_{1,25}K_1}{L_{1,25}V_1}\}/a$$

244 <u>Goodness of fit</u>

- 245 We calculated the following metrics in order to evaluate the goodness of fit between our
- 246 mathematical model and the experimental data:
- 247 Sum of squares due to regression: $SSR = \sum_{i} (\hat{x}_{i} \overline{x})^{2}$
- 248 Total sum of squares about the mean: $SST = \sum (x_i \overline{x})^2$
- 249 Sum of squared errors: $SSE = \sum (x_i \hat{x}_i)^2$
- 250 Data on goodness of fit is provided in the Results section as appropriate.

251 *Estimating relative 24-hydroxylase activity*

Equation (3) expresses relative 24-hydroxylase activity (*h*) as a function of the 25(OH)D level.

However, total 25(OH)D levels are affected by inter-individual variation in VDBP levels, a

factor which is not included in our model. Accordingly, we replaced 25(OH)D levels by the ratio

of 25(OH)D/1,25(OH)₂D. The 25(OH)D/1,25(OH)₂D ratio is independent of VDBP level and

provides an index of free levels of 25(OH)D. To normalize values of this ratio to correspond to

values of total 25(OH)D, we first divided individual values of the 25(OH)D/1,25(OH)₂D by a

normalization factor [the mean value of the 25(OH)D/1,25(OH)₂D ratio before administration of

259 VitD3 supplements]. We next converted individual values of the normalized

 $25(OH)D/1,25(OH)_2D$ ratio to the same units as total 25(OH)D by multiplying by a conversion

factor [the mean value of 25(OH)D before administration of VitD3 supplements].

262 <u>Statistics</u>

- A two-sided p-value <0.05 (paired t-test) was taken as the threshold for statistical significance
- without any correction for multiple comparisons. We pooled all the data before and after VitD3
- supplementation for graphing total levels of 1,25(OH)₂D and 24,25(OH)₂D as a function of total

- levels of 25(OH)D. Both Pearson and Spearman correlation coefficients were calculated using
- 267 software provided in Excel.
- 268 <u>Study approval</u>
- 269 The Clinical Trial Protocol was approved by the University of Maryland Baltimore Institutional
- 270 Review Board (FWA00007145). Written informed consent was obtained from all participants.

271 **RESULTS**

272 *Interrelationships among* 1,25(OH)₂D, 24,25(OH)₂D, and 25(OH)D.

As reported previously, mean (\pm SEM) total plasma levels of both 25(OH)D and 24,25(OH)₂D

- increased significantly in response to VitD3 supplementation: from 16.5±1.6 to 44.3±5.5 ng/mL
- 275 (p=0.0006) for 25(OH)D and from 1.0 ± 0.1 to 4.3 ± 0.6 ng/mL (p=0.0002) for 24,25(OH)₂D (13).
- 276 We observed consistent increases in total levels of 25(OH)D and 24,25(OH)₂D (Figs. 1A and
- 1B). In contrast, mean total plasma levels of 1,25(OH)₂D did not change in response to VitD3
- 278 supplements (43.8±3.6 pg/mL versus 44.9±4.1 pg/mL; p=0.7) (Fig. 1C) (13). This observation
- 279 provides strong evidence of the effectiveness of homeostatic mechanisms regulating levels of
- 280 1,25(OH)₂D. Therefore, we conducted exploratory analyses to further investigate physiological
- 281 mechanisms mediating this homeostatic regulation.
- For this analysis, we pooled data on VitD metabolites including data obtained both before and
- after VitD3 supplementation (Fig. 2). Although there was no significant correlation between total
- plasma levels of 1,25(OH)₂D and 25(OH)D (Fig. 2A), total plasma levels of 24,25(OH)₂D
- increased as a function of total plasma 25(OH)D levels (Fig. 2B).
- 286 <u>A critical role for regulation of 24-hydroxylase activity in homeostatic regulation of 1,25(OH)₂D</u>
- 287 We considered possible mechanisms that might contribute to the observed sigmoid shape of the
- curve relating total 24,25(OH)₂D levels to total 25(OH)D levels (Fig. 2B). If the 24-hydroxylase
- enzyme (CYP24A1) followed simple Michaelis-Menten kinetics, one might have predicted that
- the relationship between plasma levels of $24,25(OH)_2D$ and 25(OH)D would have been
- described by a hyperbola (Fig. 3A, solid curve) rather than a sigmoid curve (Fig. 3A, dashed
- 292 curve). The observed sigmoid curve approaches an asymptote at high levels of 25(OH)D most

likely a reflection of the saturability of the 24-hydroxylase enzyme (CYP24A1). What can 293 explain the relative underproduction of 24,25(OH)₂D at low levels of 25(OH)D as compared to 294 what would have been predicted by simple Michaelis-Menten kinetics? As suggested by others 295 (18, 23, 28), we hypothesized that expression of 24-hydroxylase enzyme is regulated, with low 296 297 24-hydroxylase activity occurring when 25(OH)D levels are low and higher 24-hydroxylase 298 activity when 25(OH)D levels are high. We applied mathematical modeling (see Methods section) to provide quantitative estimates of the relationship between activity of the 24-299 hydroxylase enzyme and 25(OH)D levels (Fig. 3C). Our model suggests that 24-hydroxylase 300 301 activity achieves a maximum when 25(OH)D levels exceed 50 ng/mL. In contrast, VitD deficiency is associated with suppression of 24-hydroxylase activity- achieving a minimum 302 303 corresponding to ~90% suppression when 25(OH)D levels are less than 10-20 ng/mL. Our 304 mathematical model provides estimates of 24-hydroxylase activity as a function of 25(OH)D levels (Fig. 3C). The data points in Fig. 2A demonstrate substantial "scatter" around the modeled 305 curve. We hypothesize that the ~3-fold range of inter-individual variation in levels of VitD 306 binding protein (VDBP) (29) may account for the observed 3.4-fold range of total levels of 307 1,25(OH)₂D observed in this study, which in turn could account for the observed scatter for data 308 309 points in the plot of total levels of 1,25(OH)₂D versus total levels of 25(OH)D (Fig. 2A). Interestingly, the modeled curve predicts that levels of 1,25(OH)₂D begin to decrease slightly for 310 levels of $25(OH)D < \sim 15-20$ ng/mL. This "fall-off" may possibly be related to the fact that the 311 312 model does not account for development of secondary hyperparathyroidism. If the model specified that low levels of 25(OH)D would trigger increased secretion of PTH and resultant 313 314 increased 1 α -hydroxylation of 25(OH)D, it is likely that the model would predict constant levels 315 of 1,25(OH)₂D for lower levels of 25(OH)D.

316 *Validating the model using the goodness of fit*

- Equation (1) provides a good fit to the observed data as shown by the graph plotting total levels
- of $24,25(OH)_2D$ as a function of 25(OH)D (Fig. 2B). Goodness of fit is evidenced by the fact
- that the sum of the squared errors (SSE) is small relative to the total sum of the squares about the
- 320 mean (SST): SSE/SST = 0.078 (Table 2).
- 321 Moreover, equation (7) correctly predicts that 1,25(OH)₂D levels are not correlated with
- 322 25(OH)D levels (Fig. 2A). Indeed, the sum of the squared errors (SSE) is approximately equal to
- the total sum of the squares about the mean (SST): SSE/SST = 1.04 (Table 2). Furthermore, the
- value of the ratio of the sum of the squares due to regression (SSR) divided by SST = 0.094,
- suggesting that a horizontal line described by the following equation provides a good fit for the
- observed data: $1,25(OH)_2D = 44.4 \text{ pg/mL}$ (i.e., with 44.4 pg/mL being the mean level of
- 327 1,25(OH)₂D).

328 *VitD metabolite ratios are better predictive of clinical VitD status*

329 As noted in the literature, ratios of VitD metabolites are relatively independent of inter-individual

variation in VDBP levels (24, 30, 31). For example, the following equations demonstrate that the

ratio of $[1,25(OH)_2D]/[24,25(OH)_2D]$ is independent of VDBP levels:

332 (8)
$$[1,25(OH)_2D]_{total} \approx [1,25(OH)_2D]_{free} \times VDBP_{total} \times K_{1,25}$$

333 (9)
$$[24,25(OH)_2D]_{total} \approx [24,25(OH)_2D]_{free} \times VDBP_{total} \times K_{24,25}$$

334 (10)
$$\frac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}} \approx \frac{[1,25(OH)_2D]_{free}}{[24,25(OH)_2D]_{free}} \times \frac{K_{1,25}}{K_{24,25}}$$

When the $\frac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ ratio is plotted as a function of total levels of 25(OH)D, this

represents a graph of a VDBP-independent variable on the y-axis and a VDBP-dependent

variable on the x-axis (Fig. 4A). In contrast, the graph of
$$\frac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$$
 as a function of

- 338 $\frac{[25(OH)D]_{total}}{[1,25(OH)_2D]_{total}}$ plots VDBP-independent variables on both axes (Figs. 4B). This approach
- 339 minimized the contribution of inter-individual variation in VDBP levels, thereby minimizing
- 340 "scatter" of points in the graph (Fig. 4B). When $\frac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ was plotted as a function of
- 341 $\frac{[25(OH)D]_{total}}{[1,25(OH)_2D]_{total}}$, the absolute value of the Spearman correlation coefficient was quite high (ρ =-
- 0.94; p=10⁻¹⁰) (Fig. 4B). In contrast, the absolute value of the Spearman correlation coefficient

343 was lower (
$$\rho$$
=-0.83; p=2.2x10⁻⁶) when $\frac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ was plotted as a function of total levels

345 <u>Modeling VitD Metabolite Ratios</u>

Tang et al. (23) proposed that the ratio of $1,25(OH)_2D/24,25(OH)_2D$ provides an improved

assessment of clinical VitD status with a ratio \geq 51 suggesting "VitD deficiency" and a ratio of

348 35-50 suggesting "VitD insufficiency". We applied our mathematical model to predict the shape

of the curve expressing Tang's VitD metabolite ratio $(1,25(OH)_2D/1,24(OH)_2D)$ as a function of

- total levels of 25(OH)D. Our modeled curve (Fig. 4A) closely resembles the curve included in
- the publication by Tang et al. (23). Based on our modeled curve, the cutoffs proposed by Tang et
- al. correspond to total 25(OH)D levels of ~17 ng/mL for "VitD deficiency" and ~21 ng/mL for
- 353 "VitD insufficiency".
- Furthermore, our mathematical model provides a good fit to the observed data as shown by the
- graph plotting total levels of 1,25(OH)₂D/24,25(OH)₂D as a function of 25(OH)D (Fig. 4A). Two
- other VitD metabolite ratios have been proposed in the literature: $1,25(OH)_2D/25(OH)D$ (32) and
- 357 24,25(OH)₂D/25(OH)D (24, 30, 31, 33, 34). Our mathematical model predicts that the

$25(OH)D/1,25(OH)_2D$ ratio [i.e., the reciprocal of the $1,25(OH)_2D/25(OH)D$ ratio properties and the $1,25(OH)_2D/25(OH)D$ ratio properties and $1,25($	osed in
--	---------

- the literature (32)] is a near-linear function of 25(OH)D levels (Fig. 5A); the graph of the
- $24,25(OH)_2D/25(OH)D$ ratio versus 25(OH)D is predicted to be a sigmoid curve (Fig. 5B). The
- 361 modeled curves for all three VitD metabolite ratios provide good fits to observed data [SSE/SST
- 362 ratios of 0.49-0.52 (Table 2)].

363 *Correlation of relative 24-hydroxylase activity (h) with VitD metabolite ratios*

- 364 We pooled our data before and after VitD3 supplementation for each of the three VitD
- 365 metabolites. We first investigated the correlation of the calculated relative 24-hydroxylase
- activity (*h*) with total 25(OH)D levels, which gave a Spearman correlation coefficient of ρ =0.85
- 367 (p=7E-07) (Fig. 6A). We then evaluated correlations with three VitD metabolite ratios. As
- 368 expected, relative 24-hydroxylase activity (h) was perfectly correlated with the
- $25(OH)D/1, 25(OH)_2D$ ratio ($\rho=1$) since this ratio was used in our model to account for the effect
- of variation in VDBP (Fig. 6B). While 24-hydroxylase activity (h) was highly correlated with the
- 371 1,25(OH)₂D/24,25(OH)₂D ratio (ρ^2 =0.94; p=3E-13) (Fig. 6C), *h* was less well correlated with the
- 372 24,25(OH)₂D/25(OH) ratio (ρ^2 =0.67; p=3E-06) (Fig. 6D).
- 373 *Correlation of baseline PTH with baseline indices of VitD status*

Although baseline PTH levels were correlated with baseline total 25(OH)D levels before VitD3

supplementation ($R^2=0.08$; p=5E-05), the variance in 25(OH)D accounted for only 8% of the

- variance in PTH. Furthermore, the slope of the regression line was positive whereas the known
- 377 physiology predicts that the slope should be negative (Fig. 7A) with PTH levels being higher
- 378 when 25(OH)D levels are lower. Moreover, baseline PTH levels were not significantly
- correlated with the baseline $1,25(OH)_2D/24,25(OH)_2D$ ratio (R²=0.008; p=0.63) (Fig. 7B). Even

- in participants who had received VitD3 supplementation, we observed a wide range for PTH
- levels (29-85 pg/ml) suggesting that each participant has an individual setpoint for PTH levels.

382 DISCUSSION

Because of the critical importance of Ca⁺² in many biological processes, the body has evolved 383 multiple homeostatic mechanisms to maintain free serum Ca⁺² levels within a narrow 384 physiological range. Since VitD plays a critical role in mediating intestinal absorption of dietary 385 Ca⁺², homeostatic mechanisms also maintain free 1,25(OH)₂D within narrow physiological 386 387 ranges. To maintain stable levels of 1,25(OH)₂D when VitD availability is scarce, the body has two defense mechanisms: (1) to increase production of 1,25(OH)₂D by increasing PTH-induced 388 1α-hydroxylation of 25(OH)D (12, 16, 17) and/or (2) to decrease the metabolic clearance of 389 390 1,25(OH)₂D by suppressing 24-hydroxylase – the enzyme which degrades 1,25(OH)₂D and 25(OH)D (14, 15). However, as noted in The Endocrine Society's clinical practice guidelines, 391 392 VitD deficiency-induced secondary hyperparathyroidism is associated with adverse effects on bone health: VitD-induced secondary hyperparathyroidism has an adverse impact on bone health 393 by increasing "osteoclastic activity thereby creating local foci of bone weakness, which causes a 394 generalized decrease in bone mineral density, resulting in osteopenia and osteoporosis" (17). 395

396 *<u>Two lines of defense to maintain physiological levels of 1,25(OH)₂D</u>*

Based on our study's inclusion criteria, all research participants met The Endocrine Society's 397 criterion for VitD deficiency [i.e., screening $25(OH)D \le 20$ ng/mL]. While total 25(OH)D and 398 24,25(OH)₂D levels were increased significantly by VitD3 supplementation, total 1,25(OH)₂D 399 400 did not change. Moreover, levels of PTH were within normal limits at baseline and did not change when supplements were administered to correct the VitD deficiency. These data are 401 consistent with published evidence suggesting that mild-moderate VitD deficiency may not 402 403 trigger secondary hyperparathyroidism while secondary hyperparathyroidism is a characteristic feature of severe VitD deficiency [25(OH)D <10-12 ng/mL] (35-37). 404

The published literature contains many graphs displaying PTH levels as a function of total 405 25(OH)D (35, 38-41). In general, these graphs depict an increase in mean PTH levels as 406 25(OH)D levels decrease with an inflection point at total 25(OH)D levels in the range between 407 20-30 ng/mL (37). However, individual data points scatter widely above and below the mean 408 values for PTH. If one focuses on mean data, one might conclude that all individuals are 409 410 gradually becoming increasingly hyperparathyroid as total 25(OH)D decreases. However, detailed analysis of the data suggests an alternative interpretation. If one examines data points 411 412 corresponding to total 25(OH)D levels in the range of 10-20 ng/mL, the vast majority of 413 individual data points span the same wide range of PTH levels even as total 25(OH)D levels decrease (see for example Figs 2 and 3 from Mendes et al. (38)). However, the number of 414 outliers (i.e., elevated PTH levels) begins to increase as total 25(OH)D levels decrease below 415 ~ 20 ng/mL. We interpret this observation as suggesting that there is considerable inter-individual 416 variation in the setpoint for developing secondary hyperparathyroidism. When total 25(OH)D 417 levels fall below ~10 ng/mL, there is a substantial increase in both the mean level of PTH and 418 the percentage of individuals with secondary hyperparathyroidism. We hypothesize that inter-419 individual variation in VDBP levels may be an important contributor. Individuals with high 420 421 VDBP levels are predicted to have lower free 25(OH)D levels at any given level of total 25(OH)D. Thus, such individuals with high VDBP levels would be predicted to develop 422 423 secondary hyperparathyroidism at higher levels of total 25(OH)D. Accordingly, we hypothesize 424 that VDBP-independent indices of VitD status would better predict development of secondary hyperparathyroidism. Tang et al. (23) provided data suggesting that the 425 426 $1,25(OH)_2D/24,25(OH)_2D$ ratio >100 is associated with an increased risk of elevated PTH level. 427 Our data are consistent with the hypothesis that the $1,25(OH)_2D/24,25(OH)_2D$ ratio may be

better correlated with secondary hyperparathyroidism as compared to other indices of VitD statussuch as the total 25(OH)D level.

The absence of secondary hyperparathyroidism in our participants with total 25(OH)D in the 430 431 range between 11 to 19 ng/mL inspired us to investigate what other homeostatic mechanisms maintained 1,25(OH)₂D in the normal range. Analysis of our data demonstrated that the 432 433 correlation between 25(OH)D and 24,25(OH)₂D levels was defined by a sigmoid curve rather than a hyperbola. Based on this observation, we hypothesized that 24-hydroxylase expression is 434 regulated, and we designed a mathematical model to test our hypothesis. Our model 435 436 demonstrates that 24-hydroxylase activity achieves a minimum (~90% suppression) when 25(OH)D levels <10-20 ng/mL. Thus, in mild-moderate VitD deficiency, the body suppresses 24-437 hydroxylation to preserve 1,25(OH)₂D from degradation and this mechanism provides the first 438 line of defense against VitD deficiency. Interestingly, viewed from a different perspective, high 439 levels of 25(OH)D are associated with increased 24-hydroxylase activity, which provides a major 440 defense against VitD toxicity (26, 27). In the absence of secondary hyperparathyroidism, it is 441 possible that mild-moderate VitD deficiency may not represent an absolute requirement for 442 treatment with VitD supplements if the treatment objective is to promote bone health. On the 443 444 other hand, recent publications have suggested that 24,25(OH)₂D exerts a direct effect to promote healing of bone fractures (42-44). In other words, whether or not VitD deficiency 445 446 increases the risk of bone fracture (45, 46), it has been proposed that adequate levels of 447 24,25(OH)₂D may promote healing of bone fractures.

Considerable controversy exists with respect to the overall health impact of VitD status and VitD
supplementation in the general population (45-48). Published literature demonstrates that severe
VitD deficiency triggers secondary hyperparathyroidism, which in turn induces 1α-hydroxylation

23

- thereby increasing the rate of 1,25(OH)₂D biosynthesis (16, 35). Because secondary 451 hyperparathyroidism is not triggered unless VitD deficiency becomes severe [e.g., 25(OH)D 452 <10-12 ng/mL or if 1 α -hydroxylation is impaired as in chronic kidney disease, this mechanism 453 provides the second line of defense against VitD deficiency. Secondary hyperparathyroidism is 454 associated with adverse effects on bone health. This provides a strong rationale for treatment 455 456 with VitD supplements. We propose two diagnostic terms to reflect clinical differences between these two scenarios. "Sub-clinical VitD deficiency" describes a clinical condition when only the 457 first line of defense (suppression of 24-hydroxylase) has been triggered. In this manuscript, we 458 459 have used the term "mild-moderate" VitD deficiency as a synonym for the concept of subclinical VitD deficiency (i.e., suppression of 24-hydroxylase in the absence of secondary 460 hyperparathyroidism). "Overt VitD deficiency" describes a clinical condition when both lines of 461 462 defense are triggered (i.e., suppression of 24-hydroxylase plus secondary hyperparathyroidism). This is consistent with conclusions of a scientific workshop sponsored by the National Kidney 463 Foundation in 2018, which suggested that in patients with chronic kidney disease, 25(OH)D 464 levels of <15 ng/mL require VitD treatment and in the range of 15-20 ng/mL, require treatment 465 only if there is evidence of secondary hyperparathyroidism (22). 466 Which molecular mechanism(s) mediate homeostatic regulation of 24-hydroxylase activity? 467

Expression of the *CYP24A1* gene (the gene encoding 24-hydroxylase enzyme) is reported to be

469 increased by 1,25(OH)₂D and FGF23 but decreased by PTH (49). However, mean levels of total

470 1,25(OH)₂D, FGF23, and PTH did not change in response to VitD3 supplementation in our

471 clinical trial (13). Taken at face value, these observations suggest that regulation of 24-

472 hydroxylase activity may be mediated by factors other than levels of 1,25(OH)₂D, FGF23, or

473 PTH. Nevertheless, it remains possible that regulation of 24-hydroxylase activity is sensitive to

extremely small changes in levels of 1,25(OH)₂D, FGF23, or PTH, which were not captured in
our study. Furthermore, all three hormones exhibit circadian variation (50-52). Since we obtained
blood samples at only one time of day, we cannot exclude the possibility that the relevant
biomarker(s) might require measurements of circulating levels integrated over a 24-hour period.
In any case, additional research will be required to answer this interesting question.

479 *Implications for clinical diagnosis of VitD deficiency*

Although the Endocrine Society's clinical practice guidelines recommend a "one-size-fits-all" 480 481 approach based on measurements of total levels of 25(OH)D(17), this approach does not account for the substantial inter-individual variation in levels of VDBP that limits the 482 applicability of a one-size-fits-all approach. Whereas the usual clinical assays primarily reflect 483 484 protein-bound levels of VitD metabolites, it is the free levels (i.e., not bound to protein) that are biologically relevant (53). This provides a strong rationale for a *precision diagnostics* approach 485 486 wherein diagnostic criteria for VitD deficiency are adjusted for each individual based on that 487 person's circulating level of VDBP. Other factors may also be relevant: for example, individual setpoints for PTH secretion and an individual's sensitivity to biological actions of PTH (54). 488 These considerations raise challenging questions about how best to implement a precision 489 diagnostics approach to diagnose VitD deficiency and secondary hyperparathyroidism. Others 490 have suggested the potential value of using a tailored approach to assess VitD status and to guide 491 decisions about the need for VitD supplementation (55). In clinical endocrinology practice, 492 deficiency states are frequently diagnosed by documenting the activation of compensatory 493 homeostatic mechanisms. For example, hypothyroidism is diagnosed by documenting elevated 494 495 levels of TSH. Conversely, hyperthyroidism is diagnosed by documenting suppression of TSH levels (20). By basing diagnoses on whether the body's homeostatic responses have been 496

497	triggered, physicians implicitly rely on Cannon's concept of the "wisdom of the body" to
498	diagnose hormonal status. Following these precedents, one might base the diagnosis of VitD
499	deficiency on documenting the activation of the relevant homeostatic mechanisms – e.g.,
500	suppression of 24-hydroxylase activity. However, it is challenging to base the diagnosis solely on
501	measuring total 24,25(OH) ₂ D levels because of the confounding influence of inter-individual
502	variation in VDBP levels. The observed threefold inter-individual variation in levels of VDBP
503	(29) is predicted to cause a three-fold inter-individual variation in total levels of $24,25(OH)_2D$
504	even in individuals with identical levels of free $24,25(OH)_2D$. Fortunately, VitD metabolite ratios
505	are known to be independent of VDBP levels (24). Tang et al. (23) have advocated the use of the
506	$1,25(OH)_2D/24,25(OH)_2D$ ratio for this purpose. As confirmed by our mathematical model (Fig.
507	4A), VitD deficiency is associated with a dramatic increase in the $1,25(OH)_2D/24,25(OH)_2D$
508	ratio as a consequence of the marked suppression of 24-hydroxylase activity induced by VitD
509	deficiency. By providing an index of the level of 24-hydroxylase activity, the
510	1,25(OH) ₂ D/24,25(OH) ₂ D ratio provides a highly sensitive index of clinical VitD status.
511	Furthermore, because of the extremely high correlation between the $1,25(OH)_2D/24,25(OH)_2D$
512	ratio and the 25(OH)D/1,25(OH) ₂ D ratio (Fig. 4B), it seems likely that the
513	25(OH)D/1,25(OH) ₂ D ratio might also provide a useful clinical assessment of VitD status. This
514	latter ratio is based on two widely available assays [25(OH)D and 1,25(OH) ₂ D] whereas the
515	$1,25(OH)_2D/24,25(OH)_2D$ ratio requires an assay for $24,25(OH)_2D$, which is currently less
516	widely available and more expensive. Different VitD metabolite ratios have been suggested for
517	assessment of VitD status and some studies have investigated their predictive value for hard
518	clinical endpoints e.g., risk of bone fracture (31, 33). The $24,25(OH)_2D/25(OH)D$ ratio has
519	gained attention as a clinically informative substitute for total plasma 25(OH)D for assessment of

520 VitD status. Furthermore, the scientific workshop sponsored by the National Kidney Foundation 521 proposed that the 24,25(OH)₂D/25(OH)D ratio might be particularly useful in patients with CKD 522 as a surrogate for activity of 24-hydroxylase, as in this patient population 1α -hydroxylation of 523 25(OH)D is impaired (22). However, our data suggest that the 1,25(OH)₂D/24,25(OH)₂D ratio 524 may have superior predictive value as compared to the 24,25(OH)₂D/25(OH)D ratio.

525 *Interindividual variation in PTH levels*

Even in VitD-replete participants being treated with VitD3 supplements, we observed a wide 526 range of PTH levels (29-85pg/mL). Furthermore, mean levels of PTH were not significantly 527 affected by administration of VitD3 supplements in our study (47.5±4.8 pg/mL before and 528 48.4±5.1 pg/mL after VitD3 supplementation). As suggested by others (56), interindividual 529 530 variation in PTH levels may reflect variation in the setpoint for PTH secretion. Variation in dietary calcium intake may also affect PTH levels (57). These considerations create major 531 challenges in how to interpret an individual measurement of PTH. We, therefore, assessed the 532 response of PTH to VitD3 supplementation as an indication of whether a participant exhibited 533 secondary hyperparathyroidism due to VitD deficiency. While one participant exhibited a ~34% 534 decrease in PTH level in response to VitD3 supplementation, the other participants did not 535 exhibit significant suppression of PTH levels in response to VitD3 supplementation. Consistent 536 with the conclusions of Tang et al. (23), this patient with secondary hyperparathyroidism 537 exhibited the highest value of the 1,25(OH)₂D/24,25(OH)₂D ratio (110 pg/ng) observed in our 538 study. Furthermore, the 1,25(OH)₂D/24,25(OH)₂D ratio was highly correlated (ρ^2 =-0.94; p=3E-539 13) with relative 24-hydroxylase activity as calculated by our mathematical model – accounting 540 541 for 94% of the variance in relative 24-hydroxylase activity. Other indices were less well correlated: $24,25(OH)_2D/25(OH)D$ ($\rho^2=0.67$; p=3E-06) and total 25(OH)D ($\rho^2=0.72$; p=7E-07). 542

543 <u>Study design: strengths and limitations</u>

The study was designed as a crossover study to enable paired statistical analyses comparing data 544 545 obtained before versus after administration of VitD3 supplements. To minimize the impact of 546 circadian rhythms for plasma 1,25(OH)₂D, PTH, and FGF23 (50-52), all blood samples were obtained at the same time of day (~7:00 am). Using LC-MS/MS-based assays of VitD 547 548 metabolites (Quest Diagnostics and Heartland Assays), we did not detect metabolites of VitD2 in any of our participants. The absence of VitD2 metabolites simplified data interpretation by 549 avoiding potential issues related to differences between VitD2 and VitD3 (58). Data on levels of 550 551 25(OH)D and 24,25(OH)₂D were provided by Heartland Assays – a company that specializes in applying liquid chromatography and mass spectroscopy (LC-MS/MS) to conduct scientifically 552 553 rigorous and reproducible assays of VitD metabolites. Our novel mathematical model provided 554 quantitative estimates of in vivo 24-hydroxylase activity and represents another strength of the study. Furthermore, while previous publications provide data on one or another ratio of VitD 555 556 metabolites (22, 24, 30, 31), our analysis compares the predictive value of three VitD metabolite ratios: 1,25(OH)₂D/24,25(OH)₂D; 25(OH)D/1,25(OH)₂D; and 24,25(OH)₂D/25(OH)D. 557 In addition to these strengths of our study design, the study had important limitations. Although 558 our original study design proposed to study 25 participants, the impact of the COVID-19 559 pandemic necessitated a decrease in the sample size to 11 participants. Limitations associated 560 with the relatively small sample size are partially mitigated by our efforts to assure scientific 561 rigor and reproducibility of the primary data -e.g., the enhanced statistical power provided by 562 conducting paired statistical comparisons. Accordingly, many of our analyses [e.g., VitD-induced 563

changes in 25(OH)D and $24,25(OH)_2D$] demonstrated high levels of statistical significance.

565 Other analyses [e.g., comparisons for 1,25(OH)₂D and PTH] demonstrated essentially identical

28

mean values before and after VitD3 supplementation. Based on clinical guidelines of The 566 Endocrine Society, all of our participants exhibited some degree of VitD deficiency. However, 567 only one participant exhibited more severe VitD deficiency accompanied by secondary 568 hyperparathyroidism. Additional research will be required to better understand VitD homeostatic 569 mechanisms in patients with severe VitD deficiency. 570 571 We followed The Endocrine Society's clinical guidelines recommending a loading dose of VitD3 572 (i.e., 50,000 IU/week for 4 weeks) with a modification by increasing the dose in patient with BMI \geq 30 kg/m²). Some authorities have raised questions about the impact of high dose boluses 573

of VitD that transiently raise VitD concentrations to supraphysiological levels (59). However, we
minimized this concern by maintaining participants on maintenance doses of VitD3 (1000-2000
IU/day depending on BMI) for a minimum of six weeks. This allowed for a re-equilibration to a
more physiological level of VitD.

Finally, this study was designed as an outpatient study with participants free to eat *ad libitum*. 578 579 Day-to-day variation in dietary intake of calcium and phosphate may have increased variation in measurements of various endpoints – e.g., PTH or FGF23. Furthermore, since our study design 580 did not include data on dietary intake, our analysis could not investigate dietary factors as 581 covariates. We have offered some tentative hypotheses related to the necessity of VitD 582 supplements in overt VitD deficiency as compared to the possible optional nature of VitD 583 584 supplements in sub-clinical VitD deficiency. However, we acknowledge that the present study does not provide sufficient data to draw rigorous evidence-based conclusions with respect to 585 treatment recommendations. Our small pilot study is based on biomarker data rather than hard 586 587 clinical outcomes. Future research will be required to address these important clinical questions.

29

- 588 Nevertheless, we believe it is valuable to offer hypotheses based on implications derived from
- 589 underlying physiology and pathophysiology.

590 Acknowledgements

- 591 The authors gratefully acknowledge research funding provided by NIDDK and the NIH Office of
- 592 Dietary Supplements: R01DK118942, R01DK118942-02S1, and T32DK098107. We are also
- 593 grateful to the staff at University of Maryland's Amish Research Clinic and to the members of the
- 594 Old Order Amish Community in Lancaster, PA who participated in this clinical trial.

595 Data Availability

- 596 Primary data will be made available upon request to qualified academic investigators for research
- 597 purposes under a Data Transfer Agreement to protect research participants' confidential
- 598 information.

599 Table 1. Parameters of the mathematical model.

Model	Definitions
parameters	
α	A model parameter to facilitate fitting the equation to the observed data
h	Relative 24-hydroxylase activity
K1	Michaelis-Menten constant for 1α-hydroxylase with 25(OH)D as substrate
K24	Michaelis-Menten constant for 24-hydroxylase enzyme with 25(OH)D as substrate (to fit hyperbolic curve)
L1,25	Analog of Michaelis-Menten constant for 24-hydroxylase enzyme with 1,25(OH) ₂ D as substrate (to fit sigmoid curve)
L24	Analog of Michaelis-Menten constant for 24-hydroxylase enzyme with 25(OH)D as substrate (to fit sigmoid curve)
m(1,25)	First order rate constant for metabolic clearance of 1,25(OH) ₂ D
m(24,25)	First order rate constant for metabolic clearance of 24,25(OH) ₂ D
S(1,25)	$1,25(OH)_2D$ concentration
S(24,25)	$24,25(OH)_2D$ concentration
S(25)	25(OH)D concentration
V1	Maximal velocity for 1a-hydroxylase with 25(OH)D as substrate
V24	Maximal velocity for 24-hydroxylase with 25(OH)D as substrate (to fit hyperbolic curve)
W1,25	Maximal velocity for 24-hydroxylase with 1,25(OH) ₂ D as substrate (to fit sigmoid curve)
W24	Maximal velocity for 24-hydroxylase with 25(OH)D as substrate (to fit sigmoid curve)

600

601 Table 2. Goodness of fit for mathematical model equations. The Table includes metrics for the

602 goodness of fit for the modeling equations for 1,25(OH)₂D (Fig. 2A) and 24,25(OH)₂D (Fig. 2B)

as well as the goodness of fit for modeling of three VitD metabolite ratios (Figs. 4A, 5A, and

604 5B).

	24,25(OH)D	1,25(OH) ₂ D	1,25(OH) ₂ D/ 24,25(OH) ₂ D	25(OH)D/ 1,25(OH) ₂ D	24,25(OH) ₂ D/ 25(OH)D
Sum of squares due to regression (SSR) ^a	113	315	809	3.37	0.150
Total sum of squares about mean (SST) ^b	105	3341	849	3.22	0.151
Sum of squared errors (SSE) °	8.2	3483	412	1.66	0.079
Ratio of SSE/SST	0.078	1.04	0.49	0.52	0.52
Ratio of SSR/SST	1.08	0.094	0.95	1.05	0.995

605

$$SSR = \sum (\widehat{x}_i - \overline{x})^2$$

606 ^b
$$SST = \sum (x_i - \overline{x})^2$$

$$607 \quad ^{\circ} SSE = \sum (x_i - \hat{x}_i)^2$$

608 Where x_i represents individual observed total levels of VitD metabolites, \hat{x}_i represents individual

609 predicted total levels of VitD metabolites, and \overline{x} represents the mean of observed total levels of 610 VitD metabolites.

611 FIGURE LEGENDS

Figure 1. Impact of VitD3 supplementation on total levels of VitD metabolites. Healthy participants (N=11) were recruited based on meeting the Endocrine Society's criterion of VitD deficiency [25(OH)D \leq 20 ng/mL]. Total levels of VitD metabolites were assayed before and after participants received VitD3 supplements (13): 25(OH)D (panel A), 24,25(OH)₂D (panel B), and 1,25(OH)₂D (panel C). Data are presented as means ± SEM; p-values were calculated using a two-tailed t-test for paired data.

618

619 Figure 2. Total levels of 1,25(OH)₂D and 24,25(OH)₂D as a function of total levels of

620 **25(OH)D.** Panels A and B present pooled data for individual participants when they were VitD

deficient (gray circles) and after they received VitD3 supplements (black circles). 1,25(OH)₂D

622 (panel A) and 24,25(OH)₂D (panel B) are plotted as a function of total levels of 25(OH)D. The

623 text box in panel B presents the Spearman correlation coefficient (ρ). The curves represent the

equations derived from our mathematical model: equation (1) in Panel A and equation (7) in

Panel B. Values of parameters for Equation (1): $W_{24}=8$ ng/mL; $L_{24}=40$ ng/mL; and $\alpha=0.1$. Values

626 for parameters for Equation (7): $W_{1,25}$ =40 ng/mL; $L_{1,25}$ =60 ng/mL; V_1 =40; K=60 ng/mL; α=0.1;

627 and $m_{1,25}=1$.

628

629 Figure 3. Assumptions underlying mathematical model: regulation of 24-hydroxylase

630 activity in response to clinical VitD status. Panel A depicts curves corresponding to equations

631 (1) and (2) [sigmoid and hyperbola, respectively]. Panel B depicts a family of hyperbolas

632 [equation (2)] corresponding to varying degrees of induction from 10-100% of maximal

633	induction of 24-hydroxylase activity. Panel C depicts equation (3), which is the fractional
634	induction of 24-hydroxylase activity relative to the maximal level of induction as a function of
635	25(OH)D. Values of parameters for Equation (1): $W_{24}=8$ ng/mL; $L_{24}=40$ ng/mL; and $\alpha=.0.1$.
636	Values for parameters for Equation (2): $V_{24}=10$ and $K_{24}=20$ ng/mL. Values of parameters for
637	Equation (3) $m(24,25)=1$; other parameters the same as for Equations (1) and (2).
638	
639	Figure 4. The 1,25(OH)2D/24,25(OH)D and 25(OH)D/1,25(OH)2D ratios reflect clinical
640	VitD status. The graphs summarize data from individual participants when they were VitD
641	deficient (gray circles) and after they received VitD3 supplements (black circles). Panel A depicts
642	the $1,25(OH)_2D/24,25(OH)_2D$ ratio as a function of total $25(OH)D$. The modeled curve was
643	calculated as the ratio of modeled values for 1,25(OH) ₂ D [equation (7)] divided by modeled
644	values of 24,25(OH) ₂ D [equation (1)]. Panel B depicts 1,25(OH) ₂ D/24,25(OH) ₂ D ratio as a
645	function of 25(OH)D/1,25(OH) ₂ D ratio. The fitted curves were calculated by GraphPad Prism
646	software. Text boxes indicate Spearman correlation coefficients and p-values for the correlations.

647

648	Figure 5. VitD metabolite ratios [25(OH)D/1,25(OH)2D and 24,25(OH)2D/25(OH)D] as a
649	function of the total levels of 25(OH)D. The graphs summarize data from individual
650	participants when they were VitD deficient (gray circles) and after they received VitD3
651	supplements (black circles). Panel A depicts the 25(OH)D/1,25(OH)2D ratio as a function of total
652	25(OH)D. The modeled curve was calculated as a linear regression using GraphPad Prism
653	software. Panel B depicts 24,25(OH) ₂ D/25(OH)D ratio as a function of 25(OH)D. The modeled

35

curve was calculated as modeled values for 24,25(OH)₂D [equation (1)] divided by assumed
values of 25(OH)D.

656

Figure 6. Correlation between relative 24-hydroxylase activity (h) and indices of VitD 657 status. Panels A-D present pooled data when participants were VitD deficient (gray circles) and 658 659 after they received VitD3 supplementation (black circles). The text boxes below the panels present two Spearman correlation coefficients and two p-values. The first bullet points 660 661 correspond to the correlation between 24-hydroxylase and each of the VitD status indices at baseline before participants received VitD3 supplementation. The second bullet points 662 correspond to the correlation between 24-hydroxylase and each of the VitD status indices based 663 on the pooled data (both before and after VitD3 supplementation). The curves in the graphs were 664 based on modeling of the pooled data. 665

666

Figure 7. Correlation between PTH and different indices of VitD status. Panels A and B 667 depict correlations of baseline PTH levels with baseline total 25(OH)D (panel A) or baseline 668 669 1,25(OH)₂D/24,25(OH)₂D ratio (panel B) before participants received VitD3 supplementation. One participant (designated by the gray square symbol) exhibited secondary 670 hyperparathyroidism at baseline as evidenced by a 33% decrease in PTH levels in response to 671 VitD3 supplementation. There was no statistically significant change in mean PTH levels in 672 response to VitD3 supplementation (13). Interestingly, the participant with secondary 673 hyperparathyroidism exhibited the highest baseline 1,25(OH)₂D/24,25(OH)₂D ratio among all 674 the participants in our study (gray square in panel B). 675

676 **REFERENCES**

677

- Christakos S, Dhawan P, Porta A, Mady LJ, and Seth T. Vitamin D and intestinal calcium
 absorption. *Mol Cell Endocrinol.* 2011;347(1-2):25-9.
- 680 2. Fleet JC. Vitamin D-Mediated Regulation of Intestinal Calcium Absorption. *Nutrients*.
- 681 2022;14(16).
- 682 3. Christakos S, Li S, De La Cruz J, Shroyer NF, Criss ZK, Verzi MP, et al. Vitamin D and
 683 the intestine: Review and update. *J Steroid Biochem Mol Biol.* 2020;196:105501.
- 4. Fleet JC. The role of vitamin D in the endocrinology controlling calcium homeostasis.
- 685 *Mol Cell Endocrinol.* 2017;453:36-45.
- 5. Chick HD, E.G.; Hume, M.; Mackay, H.M.M.; Smith, H.H.; Wimberger, H. The
- 687aetiology of rickets in infants: Prophylactic and curative observations at the Vienna
- 688 University Kinderklinik. *The Lancet*. 1922:7-11.
- 6. Rajakumar K. Vitamin D, cod-liver oil, sunlight, and rickets: a historical perspective.
 690 *Pediatrics*. 2003;112(2):e132-5.
- Miller WL, and Imel EA. Rickets, Vitamin D, and Ca/P Metabolism. *Horm Res Paediatr*.
 2022;95(6):579-92.
- 8. Bikle DD. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E,
- et al. eds. *Endotext*. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000-2023,
 MDText.com, Inc.; 2000.
- 696 9. Cannon WB. *The wisdom of the body*. Norton and Company Limited, W. W.; 1963.
- 10. Davies KJ. Adaptive homeostasis. *Mol Aspects Med.* 2016;49:1-7.

698	11.	Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann
699		<i>Epidemiol</i> . 2009;19(2):73-8.

- 12. Young K, Beggs MR, Grimbly C, and Alexander RT. Regulation of 1 and 24
- 701 hydroxylation of vitamin D metabolites in the proximal tubule. *Exp Biol Med*
- 702 (*Maywood*). 2022;247(13):1103-11.
- 13. Shahidzadeh Yazdi Z, Streeten EA, Whitlatch HB, Montasser ME, Beitelshees AL, and
- Taylor SI. Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse
- ros effects on 1,25-dihydroxyvitamin D and PTH. *J Clin Endocrinol Metab.* 2023.
- Jones G, Strugnell SA, and DeLuca HF. Current understanding of the molecular actions
 of vitamin D. *Physiol Rev.* 1998;78(4):1193-231.
- 15. Jones G, Prosser DE, and Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase
- 709 (CYP24A1): its important role in the degradation of vitamin D. *Arch Biochem Biophys*.
 710 2012;523(1):9-18.
- 16. Brenza HL, Kimmel-Jehan C, Jehan F, Shinki T, Wakino S, Anazawa H, et al. Parathyroid
- hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter.

713 *Proc Natl Acad Sci U S A*. 1998;95(4):1387-91.

- 17. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et
- al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society
 clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96(7):1911-30.
- 18. Tanaka Y, and DeLuca HF. Stimulation of 24,25-dihydroxyvitamin D3 production by
- 718 1,25-dihydroxyvitamin D3. *Science*. 1974;183(130):1198-200.

719	19.	Tahaka Y, Lorenc RS, and DeLuca HF. The role of 1,25-dihydroxyvitamin D3 and
720		parathyroid hormone in the regulation of chick renal 25-hydroxyvitamin D3-24-
721		hydroxylase. Arch Biochem Biophys. 1975;171(2):521-6.
722	20.	Ladenson PW. Diseases of the thyroid gland. Clin Endocrinol Metab. 1985;14(1):145-73.
723	21.	Raff H, and Carroll T. Cushing's syndrome: from physiological principles to diagnosis
724		and clinical care. J Physiol. 2015;593(3):493-506.
725	22.	Melamed ML, Chonchol M, Gutiérrez OM, Kalantar-Zadeh K, Kendrick J, Norris K, et
726		al. The Role of Vitamin D in CKD Stages 3 to 4: Report of a Scientific Workshop
727		Sponsored by the National Kidney Foundation. Am J Kidney Dis. 2018;72(6):834-45.
728	23.	Tang JCY, Jackson S, Walsh NP, Greeves J, and Fraser WD. The dynamic relationships
729		between the active and catabolic vitamin D metabolites, their ratios, and associations with
730		PTH. Sci Rep. 2019;9(1):6974.
731	24.	Ginsberg C, Hoofnagle AN, Katz R, Becker JO, Kritchevsky SB, Shlipak MG, et al. The
732		Vitamin D Metabolite Ratio Is Independent of Vitamin D Binding Protein Concentration.
733		<i>Clin Chem.</i> 2021;67(2):385-93.
734	25.	Biancuzzo RM, Clarke N, Reitz RE, Travison TG, and Holick MF. Serum concentrations
735		of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 in response to vitamin D2
736		and vitamin D3 supplementation. J Clin Endocrinol Metab. 2013;98(3):973-9.
737	26.	Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, et al. Mutations in
738		CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. 2011;365(5):410-21.
739	27.	Streeten EA, Zarbalian K, and Damcott CM. CYP24A1 mutations in idiopathic infantile
740		hypercalcemia. N Engl J Med. 2011;365(18):1741-2; author reply 2-3.

741 28. Batacchi Z. Robinson-Cohen C. Hoofnagle AN. Isakova I. Kestenbaum B. Ma

- al. Effects of Vitamin D(2) Supplementation on Vitamin D(3) Metabolism in Health and
- 743 CKD. Clin J Am Soc Nephrol. 2017;12(9):1498-506.
- 29. Robinson-Cohen C, Zelnick LR, Hoofnagle AN, Lutsey PL, Burke G, Michos ED, et al.
- Associations of Vitamin D-Binding Globulin and Bioavailable Vitamin D Concentrations
- 746 With Coronary Heart Disease Events: The Multi-Ethnic Study of Atherosclerosis

747 (MESA). J Clin Endocrinol Metab. 2017;102(8):3075-84.

- 30. Ahmed LHM, Butler AE, Dargham SR, Latif A, Chidiac OM, Atkin SL, et al. Vitamin
- D(3) metabolite ratio as an indicator of vitamin D status and its association with diabetes
 complications. *BMC Endocr Disord*. 2020;20(1):161.
- Ginsberg C, Hoofnagle AN, Katz R, Hughes-Austin J, Miller LM, Becker JO, et al. The
 Vitamin D Metabolite Ratio Is Associated With Changes in Bone Density and Fracture

753 Risk in Older Adults. *J Bone Miner Res.* 2021;36(12):2343-50.

- Meng L, Su C, Shapses SA, and Wang X. Total and free vitamin D metabolites in patients
 with primary hyperparathyroidism. *J Endocrinol Invest.* 2022;45(2):301-7.
- 33. Bansal N, Katz R, Appel L, Denburg M, Feldman H, Go AS, et al. Vitamin D Metabolic
- 757 Ratio and Risks of Death and CKD Progression. *Kidney Int Rep.* 2019;4(11):1598-607.
- 758 34. Ginsberg C, Katz R, de Boer IH, Kestenbaum BR, Chonchol M, Shlipak MG, et al. The
- 759 24,25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: The cardiovascular
 760 health study. *Bone*. 2018;107:124-30.
- 761 35. Jesudason D, Need AG, Horowitz M, O'Loughlin PD, Morris HA, and Nordin BE.
- 762 Relationship between serum 25-hydroxyvitamin D and bone resorption markers in
- vitamin D insufficiency. *Bone*. 2002;31(5):626-30.

764	36.	Jones G. 100 YEARS OF VITAMIN D: Historical aspects of vitamin D. Endocr Connect.
765		2022;11(4).

- 766 37. Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, et al.
- 767 IOM committee members respond to Endocrine Society vitamin D guideline. *J Clin*
- *Endocrinol Metab.* 2012;97(4):1146-52.
- 769 38. Mendes MM, Hart KH, Lanham-New SA, and Botelho PB. Suppression of Parathyroid
- 770 Hormone as a Proxy for Optimal Vitamin D Status: Further Analysis of Two Parallel
- 771 Studies in Opposite Latitudes. *Nutrients*. 2020;12(4).
- 39. Looker AC, and Gunter EW. Hypovitaminosis D in medical inpatients. *N Engl J Med.*1998;339(5):344-5; author reply 5-6.
- 40. Shah S, Chiang C, Sikaris K, Lu Z, Bui M, Zebaze R, et al. Serum 25-Hydroxyvitamin D
 Insufficiency in Search of a Bone Disease. *J Clin Endocrinol Metab.* 2017;102(7):2321-
- 776

8.

- Gallagher JC, Jindal PS, and Smith LM. Vitamin D supplementation in young White and
 African American women. *J Bone Miner Res.* 2014;29(1):173-81.
- Demay MB. The good and the bad of vitamin D inactivation. *J Clin Invest.*2018;128(9):3736-8.
- 43. Martineau C, Kaufmann M, Arabian A, Jones G, and St-Arnaud R. Preclinical safety and
- efficacy of 24R,25-dihydroxyvitamin D(3) or lactosylceramide treatment to enhance
 fracture repair. *J Orthop Translat.* 2020;23:77-88.
- 44. Martineau C, Naja RP, Husseini A, Hamade B, Kaufmann M, Akhouayri O, et al. Optimal
- bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule

786 FAM57B2. J Clin Invest. 2018;128(8):3546-57.

787	45.	LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, et al. Supplemental
788		Vitamin D and Incident Fractures in Midlife and Older Adults. N Engl J Med.
789		2022;387(4):299-309.
790	46.	Cummings SR, and Rosen C. VITAL Findings - A Decisive Verdict on Vitamin D
791		Supplementation. N Engl J Med. 2022;387(4):368-70.
792	47.	Bouillon R, Manousaki D, Rosen C, Trajanoska K, Rivadeneira F, and Richards JB. The
793		health effects of vitamin D supplementation: evidence from human studies. Nat Rev
794		Endocrinol. 2022;18(2):96-110.
795	48.	Pfotenhauer KM, and Shubrook JH. Vitamin D Deficiency, Its Role in Health and
796		Disease, and Current Supplementation Recommendations. J Am Osteopath Assoc.
797		2017;117(5):301-5.
798	49.	Meyer MB, and Pike JW. Mechanistic homeostasis of vitamin D metabolism in the
799		kidney through reciprocal modulation of Cyp27b1 and Cyp24a1 expression. J Steroid
800		Biochem Mol Biol. 2020;196:105500.
801	50.	Blau JE, Bauman V, Conway EM, Piaggi P, Walter MF, Wright EC, et al. Canagliflozin
802		triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a
803		randomized crossover study. JCI Insight. 2018;3(8).
804	51.	el-Hajj Fuleihan G, Klerman EB, Brown EN, Choe Y, Brown EM, and Czeisler CA. The
805		parathyroid hormone circadian rhythm is truly endogenousa general clinical research
806		center study. J Clin Endocrinol Metab. 1997;82(1):281-6.
807	52.	Kawai M, Kinoshita S, Shimba S, Ozono K, and Michigami T. Sympathetic activation
808		induces skeletal Fgf23 expression in a circadian rhythm-dependent manner. J Biol Chem.
809		2014;289(3):1457-66.

810	53.	Bikle DD. The Free Hormone Hypothesis: When, Why, and How to Measure the Free
811		Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status. JBMR
812		Plus. 2021;5(1):e10418.
813	54.	Lemoine S, Figueres L, Bacchetta J, Frey S, and Dubourg L. Calcium homeostasis and
814		hyperparathyroidism: Nephrologic and endocrinologic points of view. Ann Endocrinol
815		(Paris). 2022;83(4):237-43.
816	55.	Bilezikian JP, Formenti AM, Adler RA, Binkley N, Bouillon R, Lazaretti-Castro M, et al.
817		Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?
818		<i>Rev Endocr Metab Disord</i> . 2021;22(4):1201-18.
819	56.	Robinson-Cohen C, Lutsey PL, Kleber ME, Nielson CM, Mitchell BD, Bis JC, et al.
820		Genetic Variants Associated with Circulating Parathyroid Hormone. J Am Soc Nephrol.
821		2017;28(5):1553-65.
822	57.	Rejnmark L, Vestergaard P, Heickendorff L, and Mosekilde L. Determinants of plasma
823		PTH and their implication for defining a reference interval. Clin Endocrinol (Oxf).
824		2011;74(1):37-43.
825	58.	Tripathi A, Ansari M, Dandekar P, and Jain R. Analytical methods for 25-hydroxyvitamin
826		D: advantages and limitations of the existing assays. J Nutr Biochem. 2022;109:109123.
827	59.	Mazess RB, Bischoff-Ferrari HA, and Dawson-Hughes B. Vitamin D: Bolus Is Bogus-A
828		Narrative Review. JBMR Plus. 2021;5(12):e10567.

829















